Serum in vivo and in vitro activity of single dose of ertapenem in surgical obese patients for prevention of SSIs

Obesity Surgery

Volumn 23, Issue 7, 2013, Pages 911-919

  De Werra, Carlo ^a,b   Di Micco, Rosa ^a   Pilone, Vincenzo ^a   Formato, Antonio ^a   Montella, Emma ^a,b   Lambiase, Antonietta ^a,b   Cerbone, Domenica ^a   Catania, Maria Rosaria ^a,b   Forestieri, Pietro ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antibiotics; Ertapenem; Obesity; Surgical site infections

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE;

ABDOMINAL SURGERY; ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BARIATRIC SURGERY; CITROBACTER FREUNDII; CONTROLLED STUDY; DEVICE REMOVAL; DRUG EFFICACY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; SURGICAL INFECTION;

ABDOMEN; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BARIATRIC SURGERY; BETA-LACTAMS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; ITALY; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY, MORBID; PRACTICE GUIDELINES AS TOPIC; PROTEUS MIRABILIS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 84878846013     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0879-1     Document Type: Article

References (31)

1. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27(2):97-132.
2. Chopra T, Zhao JJ, Alangaden G, et al. Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):317-28.
3. Anaya DA, Dellinger EP. The obese surgical patient: a susceptible host for infection. Surg Infect (Larchmt). 2006;7(5):473-80.
4. de Werra C, Schiavone D, Di Micco R, et al. Surgical site infections in Italy. Infez Med. 2009;17(4):205-18.
5. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53 Suppl 2:ii23-8.
6. Itani KMF, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640-51.
7. Goldstein EJ, Citron DM, Merriam CV, et al. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs ertapenem prophylaxis. Surg Infect. 2009;10:111-8.
8. Periti P, Mazzei T, Tonelli F. Single-dose cefotetan vs. multiple doses cefoxitin antimicrobial prophylaxis in colorectal surgery: results of a prospective, multicenter, randomized study. Dis Colon Rectum. 1989;32:121-7.
9. Periti P, Tonelli F, Mazzei T, et al. Antimicrobial chemoimmuno- prophylaxis in colorectal surgery with cefotetan and thymostimulin: prospective, controlled multicenter study. J Chemother. 1993;5:37-42.
10. Jagelman DG, Fabian TC, Nichols RL, et al. Single-dose cefotetan versus multiple-dose cefoxitin as prophylaxis in colorectal surgery. Am J Surg. 1988;155:71-6.
11. Itani KM, Jensen EH, Finn TS, et al. Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect. 2008;9:131-7.
12. Martin C, Portet C, Lambert D, et al. Pharmacokinetics and tissue penetration of single-dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992;36:1115-8.
13. de Lalla F. Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem. Ther Clin Risk Manag. 2009;5:829-39.
14. Topaloglu S, Avsar FM, Ozel H, et al. Comparison of bariatric and non-bariatric elective operations in morbidly obese patients on the basis of wound infection. Obes Surg. 2005;15(9):1271-6.
15. Dindo D, Muller MK, Weber M, et al. Obesity in general elective surgery. Lancet. 2003;361(9374):2032-5.
16. Myles TD, Gooch J, Santolaya J. Obesity as an independent risk factor for infectious morbidity in patients who undergo cesarean delivery. Obstet Gynecol. 2002;100(5 Pt 1):959-64.
17. Czupryniak L, Strzelczyk J, Pawlowski M, et al. Mild elevation of fasting plasma glucose is a strong risk factor for postoperative complications in gastric bypass patients. Obes Surg. 2004;14(10):1393-7.
18. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004;136(4):738-47.
19. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother. 2003;52:331-44.
20. Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989;106:750-6.
21. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84:1053-60.
22. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997;25:112-8.
23. Chen M, Nafziger AN, Drusano GL, et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006;50(4):1222-7.
24. Clinical and Laboratory Standards Institute (CLSI). (2010). Performance standards for antimicrobial susceptibility testing. M100-S20. Wayne. PA: CLSI
25. Siegel JD, Rhinehart E, Jackson M, et al. Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control. 2007;35:165-93.
26. Nagashima Y, Sendo A, Shimakura K, et al. Antibacterial factors in skin mucus of rabbtfishes. J Fish Biol. 2001;58:1761-5.
27. Fanghua W, Ruijun L, Mingquan XX, et al. The serum rabbitfish (Siganus oramin) has antimicrobial activity to some pathogenic organisms and a novel serum L-amino acid oxidase is isolated. Fish & Shellfish Immunol. 2011;30(4-5):1095-108.
28. Jensen JA, Goodson WH, Hopf HW, et al. Cigarette smoking decreases tissue oxygen. Arch Surg. 1991;126:1131-4.
29. Hopf HW, Hunt TK, West JM, et al. Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg. 1997;132:997-1004.
30. Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol. 2001;22:607-12.
31. Kwon S, Thompson R, Dellinger P, et al. Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013;257(1):8-14.